Literature DB >> 12154033

Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).

Shyh-Min Huang1, Jing Li, Eric A Armstrong, Paul M Harari.   

Abstract

ZD1839 ("Iressa") is an orally-active, selective epidermal growth factor receptor-tyrosinekinase inhibitor. We evaluated the antitumor activity of ZD1839 in combination with radiation in human squamous cell carcinomas (SCCs) of the head and neck. ZD1839 produced a dose-dependent inhibition of cellular proliferation in human SCCs grown in culture. Flow cytometry analysis of cell cycle progression confirmed the accumulation of cells in G(1) phase after exposure to ZD1839. Clonogenic analysis demonstrated that treatment of SCCs with ZD1839 reduced cell survival after radiation exposure. Flow cytometric analysis further demonstrated that treatment of SCCs with ZD1839 amplified radiation-induced apoptosis. Tumor xenograft studies confirmed that oral administration of ZD1839, or focal radiation, resulted in partial and transient tumor regression in both SCC-1 and SCC-6 xenografts. In contrast, profound tumor regression and regrowth delay was observed in mice treated with the combination of ZD1839 and radiation. To examine antiangiogenic effects, we studied the impact of ZD1839 on human umbilical vascular endothelial cells (HUVECs). In the presence of reconstituted Matrigel matrix, HUVECs established a capillary-like network structure (tube formation). Treatment with ZD1839 reduced the cell-to-cell interaction of HUVECs, resulting in disruption of tube formation. The effect of ZD1839 was further examined using an in vivo tumor xenograft model of angiogenesis (Matrigel plug) in athymic mice. Systemic treatment with ZD1839 significantly inhibited tumor-induced neovascularization across the Matrigel plug. Taken together, these results suggest that the antitumor activity of ZD1839 in combination with radiation appears to derive from not only proliferative growth inhibition (with associated cell cycle arrest and enhancement of radiation-induced apoptosis) but also from inhibition of tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154033

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.

Authors:  Tim J Kruser; Eric A Armstrong; Amol J Ghia; Shyhmin Huang; Deric L Wheeler; Robert Radinsky; Daniel J Freeman; Paul M Harari
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

2.  Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

Authors:  Carter Van Waes; Clint T Allen; Deborah Citrin; David Gius; A Dimetrios Colevas; Nancy A Harold; Susan Rudy; Liesl Nottingham; Christine Muir; Zhong Chen; Anurag K Singh; Janet Dancey; John C Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-30       Impact factor: 7.038

Review 3.  Linking the history of radiation biology to the hallmarks of cancer.

Authors:  Mary-Keara Boss; Robert Bristow; Mark W Dewhirst
Journal:  Radiat Res       Date:  2014-05-08       Impact factor: 2.841

Review 4.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

5.  Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

Authors:  Lorella Bonaccorsi; Sara Marchiani; Monica Muratori; Gianni Forti; Elisabetta Baldi
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-16       Impact factor: 4.553

6.  Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

Authors:  Asa Liljegren Sundberg; Ylva Almqvist; Anna Orlova; Erik Blomquist; Holger J Jensen; Lars Gedda; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

7.  Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.

Authors:  Toshimitsu Tanaka; Anupama Munshi; Colin Brooks; Jenny Liu; Marvette L Hobbs; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

Review 8.  An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response.

Authors:  Benjamin Titz; Robert Jeraj
Journal:  Phys Med Biol       Date:  2008-08-01       Impact factor: 3.609

9.  Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.

Authors:  George J Cerniglia; Nabendu Pore; Jeff H Tsai; Susan Schultz; Rosemarie Mick; Regine Choe; Xiaoman Xing; Turgut Durduran; Arjun G Yodh; Sydney M Evans; Cameron J Koch; Stephen M Hahn; Harry Quon; Chandra M Sehgal; William M F Lee; Amit Maity
Journal:  PLoS One       Date:  2009-08-06       Impact factor: 3.240

Review 10.  Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.

Authors:  A Katz; P Zalewski
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.